Notice of Results
CelLBxHealth plc will announce its preliminary results for the year ended 31 December 2025 on Monday, 22 June 2026, with the Chief Executive Officer providing an overview via an online investor presentation at 11:00 BST on the same day. The company, a CTC intelligence specialist, focuses on circulating tumour cell solutions for research, drug development, and clinical oncology, utilizing its Parsortix platform across product sales, laboratory services, and lab-developed tests.
Select text to share a quote on X · sign in to keep highlights & notes in your CLBX notes
Guildford, UK and Plymouth Meeting, U.S. - 16 June 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, will announce its preliminary results for the year ended 31 December 2025 on Monday, 22 June 2026.
Online investor presentation
Peter Collins, Chief Executive Officer, will provide an overview of the Company's preliminary results via the Investor Meet Company platform at 11:00 BST on Monday, 22 June 2026. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 09:00 BST the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet CelLBxHealth plc via: https://www.investormeetcompany.com/cellbxhealth-plc/register
Investors who already follow CelLBxHealth plc on the Investor Meet Company platform will automatically be invited.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.